Clinical Trial Update: Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients [Phase 1, Phase 2]

View source ↗

Summary

A safety evaluation update from a Phase 1/2 gene therapy trial in Leber hereditary optic neuropathy, reporting safety outcomes without efficacy claims.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• LUMEVOI (lenadogene nolparvovec)

Snippet

Sponsor: GenSight Biologics | Conditions: Leber Hereditary Optic Neuropathy | Phase 1, Phase 2 | Status: COMPLETED